Policy resistance to harm reduction for drug users and potential effect of change
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3439 (Published 13 July 2010) Cite this as: BMJ 2010;341:c3439
- Tim Rhodes, professor of public health sociology1,
- Anya Sarang, consultant researcher2,
- Peter Vickerman, senior lecturer of mathematical epidemiology13,
- Matthew Hickman, professor of public health and epidemiology3
- 1Centre for Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine, London WC1E 8HT
- 2Andrey Rylkov Foundation for Health and Social Justice, Moscow, Russia
- 3Social Medicine, University of Bristol, Bristol
- Correspondence to: T Rhodes tim.rhodes{at}lshtm.ac.uk
- Accepted 2 June 2010
The health harms of injecting drug use include HIV, hepatitis C, bacterial infections, overdose, and substantial excess mortality. An estimated 16 million people inject drugs worldwide, 3 million of whom live in eastern Europe.1 Around 1.5 million people are infected with HIV in eastern Europe, with most infected through injecting drug use.2 The largest European epidemics are those in the Russian Federation and Ukraine, where over a third of injecting drug users are thought to be HIV positive.1 2 One contributing factor is policy resistance to harm reduction.
Epidemiologist Elizabeth Pisani and other leading commentators describe which countries are leading the way in tackling HIV infection among injecting drugs users in this 10 minute BMJ video.
Harm reduction
Harm reduction encompasses interventions and policies that seek primarily to reduce the harms of drug use without necessarily requiring abstinence from drug use. The Council of the European Union, World Health Organization, and United Nations Joint Programme on HIV/AIDS recommend a comprehensive package of harm reduction services for people who inject drugs, including programmes providing easy access to clean needles and syringes, opioid substitution treatment, and antiretroviral drugs for HIV.3 Access to opioid substitutes and syringe distribution programmes can reduce risky injecting practices and incidence of HIV.4 5 6 Opioid substitution also reduces deaths from overdose, drug related mortality, and offending. Access to antiretroviral HIV treatment improves mortality and morbidity among injecting drug users.7
A critical factor determining the effect of interventions is their coverage among target populations.8 Intervention coverage varies widely globally but is especially low in eastern Europe, where …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.